Experience with axitinib treatment in mRCC 2nd line patients

dc.contributor.authorRichter Igorcs
dc.contributor.authorDvořák Josefcs
dc.date.accessioned2020-06-08T09:42:43Z
dc.date.available10-41-2019en
dc.date.available2020-06-08T09:42:43Z
dc.date.issued2018cs
dc.date.updated29-53-2019en
dc.format.extent0cs
dc.identifier.urihttps://dspace.tul.cz/handle/15240/155921
dc.language.isoczecs
dc.relation.ispartofseries0cs
dc.subjectaxitinibcs
dc.subjectMetastatic Renal Carcinomacs
dc.titleExperience with axitinib treatment in mRCC 2nd line patientsen
dc.titleZkušenosti s léčbou axitinibem u pacientů ve 2. linii mRCCcs
local.identifier.publikace6553
Files
Collections